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Abstract
Context: Interpretation of dexamethasone suppression test (DST) may be influenced by
dexamethasone absorption and metabolism and by the altered cortisol binding.
Objective: We aimed to determine the normal ranges of free cortisol during DST in
participants without adrenal disorders and to identify the population of patients where
post-DST free cortisol measurements add value to the diagnostic workup.
Design and Setting: Cross-sectional study conducted in a tertiary medical center.
Participants: Adult volunteers without adrenal disorders (n = 168; 47 women on oral
contraceptive therapy [OCP], 66 women not on OCP, 55 men) and patients undergoing
evaluation for hypercortisolism (n = 196; 16 women on OCP).
Measurements: Post-DST dexamethasone and free cortisol (mass spectrometry) and
total cortisol (immunoassay).
Main Outcome Measures: Reference range for post-DST free cortisol, diagnostic
accuracy of post-DST total cortisol.
Results: Adequate dexamethasone concentrations (≥0.1 mcg/dL) were seen in 97.6%
volunteers and 96.3% patients. Only 25.5% of women volunteers on OCP had abnormal
post-DST total cortisol (>1.8 mcg/dL). In volunteers, the upper post-DST free cortisol
range was 48 ng/dL in men and women not on OCP, and 79 ng/dL in women on OCP.
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A 1-mg dexamethasone suppression test (DST) is a
standard-of-care endocrine test recommended in the evaluation of adrenal masses and for patients suspected to have
endogenous Cushing syndrome (1-3). The guidelines from
the European Society of Endocrinology/European Network
for the Study of Adrenal Tumours define autonomous cortisol secretion as post-DST total cortisol >5 mcg/dL and
possible autonomous cortisol secretion as post-DST cortisol between 1.8 and 5 mcg/dL (2). Patients with abnormal
post-DST cortisol are at higher risk for cardiovascular
morbidity (4), fractures (5, 6), and frailty (7), and are recommended to undergo workup to evaluate for associated
comorbidities both at baseline and follow-up (1, 2).
Interpretation of DST is affected by the dexamethasone
absorption and metabolism, with several studies reporting
a rate of 6% to 20% of false-positive results because of
inadequate dexamethasone concentrations (8-10). Another
source of false-positive results is the difference in the proportion of cortisol bound to corticosteroid binding globulin
affecting total cortisol concentrations. Free cortisol represents approximately 5% to 6% of total cortisol. The majority of cortisol is bound to the corticosteroid binding
globulin, and less so to albumin and erythrocytes. Several
conditions, such as pregnancy, liver and renal failure, and
medications, such as oral contraceptive therapy (OCP)
may affect corticosteroid-binding globulin concentrations
(11-16). This may lead to either falsely low or high total
cortisol concentrations and affect interpretation with either over or under diagnosis of adrenal insufficiency or
hypercortisolism, depending on the clinical scenario.
OCP therapy is most commonly associated with false
positives during DST, and the guidelines recommend stopping OCP for 6 weeks before performing DST (3). This can
be quite taxing for patients and can result in exacerbations
of their underlying conditions, such as hyperandrogenism
and menorrhagia, or can result in undesired pregnancy. The
value of post-DST free cortisol measurement in saliva has
been previously explored by Ueland et al, but included very
few patients treated with OCP (8).
In this study, we aimed to determine the utility of free
cortisol assessment during DST. Our objectives were: (1) to
determine the normal ranges of free cortisol during DST in

participants without adrenal disorders, including women
taking OCP and (2) to identify the population of patients
in whom post-DST free cortisol measurement add value to
the diagnostic work up of hypercortisolism.

Materials and Methods
Participants
This study protocol was approved by the institutional review board of Mayo Clinic, Rochester. We conducted this
prospective study at the Endocrine Testing Center, Mayo
Clinic Division of Endocrinology, in Rochester, Minnesota,
between January 2016 and August 2018 in adults ≥ 18 years
of age. All subjects provided a written informed consent before participation.
In brief, this was a cross-sectional study with prospective
consecutive enrollment of (1) volunteers without adrenal
disorders and (2) patients being assessed for cortisol excess
for clinical reasons. All participants underwent DST with
measurements of total and free cortisol as well as dexamethasone concentrations. After establishing the normal
ranges for post-DST free cortisol in volunteers, the cutoffs
were applied to a cohort of patients evaluated in the endocrine clinic and being assessed with DST.
Volunteers were enrolled through an advertisement
placed online within the Mayo Health System. Each volunteer was interviewed to confirm absence of adrenal disorders and exogenous glucocorticoid use within 3 months
and examined for clinical symptoms and signs of Cushing
syndrome. Careful medication history was taken to exclude medications interfering with metabolism of dexamethasone. The type and dose of oral estrogen-containing
therapy was recorded and pregnancy was excluded at time
of participation.
Patients
were
consecutively
recruited
from
Endocrinology clinic; all patients requiring DST as a part
of their clinical care were offered enrollment in the study,
and 96% of approached patients consented to participate
in this study. Pertinent clinical information for this study
was obtained through medical electronic record review and
an interview.
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When compared with post-DST free cortisol, diagnostic accuracy of post-DST total
cortisol was 87.3% (95% CI, 81.7-91.7); all false-positive results occurred in patients with
post-DST cortisol between 1.8 and 5 mcg/dL. OCP use was the only factor associated with
false-positive results (21.1% vs 4.9%, P = 0.02).
Conclusions: Post-DST free cortisol measurements are valuable in patients with optimal
dexamethasone concentrations and post-DST total cortisol between 1.8 and 5 mcg/dL.
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Total cortisol concentration
Measurement of total cortisol used a competitive binding
immune-enzymatic assay on the UniCel DxI 800 (Beckman
Coulter, Brea, California). Total cortisol measurements are
provided in milligrams per deciliter. Total cortisol after
1 mg DST in patients was considered normal if ≤1.8 mcg/
dL. In patients, total cortisol >1.8 mcg/dL were considered
to have hypercortisolism (mild hypercortisolism when total
cortisol was 1.8-5 mcg/dL and significant hypercortisolism
when >5 mcg/dL).

Dexamethasone concentration
Dexamethasone was measured by liquid/liquid extraction
followed by high-performance liquid chromatography and
detection by tandem mass spectrometry, which is commercially available through Mayo Clinic Laboratories and is
validated by USA federal Clinical Laboratory Improvement
Amendments requirements. Relevant details of the dexamethasone assay are included in supplemental Table
1. Lower limit of quantification was 0.1 mcg/dL. The
threshold for dexamethasone concentration resulting in
suppression of total cortisol was determined in healthy
volunteers. Then, this threshold was applied to determine
whether dexamethasone concentration was optimal for interpretation of DST in the patient group.

Free cortisol concentration
Free cortisol was measured by an assay developed in Mayo
Clinic Laboratories, as previously reported (17). In brief,
free cortisol was separated from its bound form without
disrupting the equilibrium of the sample using a commercially available equilibrium dialysis plate (Thermo Fisher
Scientific, Waltham, Massachusetts). Each sample well
was separated by a vertical cylinder of dialysis membrane
(molecular weight cutoff, 8000). Duplicate samples of
0.25 mL were added to each well. The adjacent chamber
was filled with dialysis buffer. After equilibrium was

reached, the dialysate was removed, and the d3-cortisol internal standard was added to the dialysate. The dialysate/
internal standard mixture was analyzed using turbo flow liquid chromatography combined with atmospheric pressure
chemical ionization and tandem mass spectrometry. Briefly,
dialysate is injected onto a 0.5 × 50 mm HTLC C18XL
column (Cohesive Technologies, Alpharetta, Georgia) before being transferred to a Zorbax XDB-C18, 4.6 × 50 mm
(Agilent Technologies, Santa Clara, California). Cortisol
and its internal standard were measured by multiple reaction monitoring (MRM) using the precursor ions of cortisol (m/z 363.2), its isotopic internal standard (m/z 366.2),
and their respective primary collision-induced fragment/
product ions (m/z121.0 for both) for sensitive and specific
quantification on an AB 5000mass spectrometer (Sciex,
Framingham, Massachusetts). A calibration curve generated from stripped serum spiked standard was included
with each batch of patient specimens. Measurements are
provided in nanograms per deciliter.
Data from volunteers without clinical evidence of
hypercortisolism were used to develop a reference range for
the free cortisol assay following the 1 mg DST. Reference
ranges for women on OCP and men and women not on
OCP were constructed after the exclusion of results when
dexamethasone concentration was <0.1 mcg/dL and after
excluding of outliers. The utility of free cortisol measurements in addition to total cortisol was then evaluated in the
patient study population.

Statistical analysis
Data were analyzed using JMP 15.1.0 software (SAS Inc.,
Cary, North Carolina). Variables were assessed for normality by the Kolmogorov-Smirnov test. All continuous
data are summarized as median and interquartile ranges
(IQR), while categorical data are summarized as a number
(percent). Subjects with missing data were excluded from
analyses. Associations between variables were assessed
using the Kruskal-Wallis test for continuous variables and
the χ 2 test or Fisher exact test for categorical variables, as
appropriate. Statistical significance was defined as P < 0.05.

Results
Volunteers
One hundred and sixty-eight volunteers participated in
this study, including 113 women (67%), median age 29.5
(IQR 26, 40) years and 55 men (33%), median age of 30
(IQR 27, 40) years, Table 1. Among women participants,
47 (42%) were taking OCP with median estradiol dose 30
mcg (IQR 20, 35).
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Medical record review was conducted to ascertain demographic parameters (sex, age, body mass index [BMI]), clinical indication for DST (in patient cohort), and whether
oral contraceptive therapy was in use (in women, type
and dose collected). All study participants were instructed
to take 1 mg of dexamethasone at 11 pm the night before
blood sample collection. Blood samples were obtained between 8 and 9 am and analyzed for total cortisol, free cortisol, and dexamethasone concentrations.
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total cortisol concentrations and sex, age, or BMI were found
(data not shown).
Following the overnight 1 mg administration of dexamethasone, volunteers demonstrated dexamethasone concentrations at a median of 0.34 ng/dL (IQR 0.25, 0.44),
with 2.4% having inadequate dexamethasone concentrations <0.1 ng/dL (Table 1, supplemental Fig. 1) (18).
Post-DST free cortisol concentration in volunteers was
at a median of 24 ng/dL (IQR 19.3, 32.0), not significantly
different among men, women not taking OCP, and women
taking OCP, respectively (21 ng/dL, 22 ng/dL, 33 ng/dL;

Table 1. Dexamethasone suppression test in volunteers
All volunteers
(n = 168)
Age, y, median (IQR)
29.5 (26, 40)
BMI, kg/m2, median (IQR)
25.4 (22.8, 29.2)
Estradiol dose, mcg, median (IQR)
≥ 30 mcg, n (%)
Dexamethasone concentration,b,c mcg/dL, me0.34 (0.25, 0.44)
dian (IQR)
Dexamethasone concentrationb,c ≥0.1 mcg/dL,
162 (97.6%)
number (%)
Total serum cortisol,b,c mcg/dL, median (IQR)
0.79 (0.60, 1.30)
Total serum cortisol > 1.8b,c mcg/dL, number (%)
18 (10.9%)
Free serum cortisol,b ng/dL, median (IQR)
24 (19.3, 32.0)

Women, taking OCPa
(n = 47)

Women, no OCP
(n = 66)

Men (n = 55)

P
value

27 (24, 30)
24.5 (22.4, 28.3)
30 (20, 35)
34 (72.3%)
0.37 (0.24, 0.43)

32 (27, 42.5)
25.1 (22.6, 29.0)
-

30 (27, 40)
26.9 (24.3, 30.5)
-

0.003
0.40
-

0.30 (0.25, 0.40)

0.38 (0.25, 0.46)

0.31

45 (95.7%)

65 (98.5%)

52 (98.1%)

0.32

1.3 (1.1, 1.9)
12 (25.5%)
33 (24.0, 47.0)

0.72 (0.58, 0.88)
3 (4.6%)
22 (19.0, 27.3)

0.64 (0.51, 0.83)
3 (5.7%)
21 (17.0, 26.0)

0.02
0.001
0.70

Abbreviations: BMI, body mass index; IQR, interquartile range; OCP, oral contraceptive pill.
a
OCP use group included all women who received estrogen-containing oral contraceptive. Women who were on progestin-only contraceptive therapy (n = 2) were
considered in the non-OCP group.
b
Dexamethasone concentration, total serum cortisol, and free serum cortisol were collected after 1 mg oral dexamethasone suppression.
c
Data unavailable for dexamethasone concentration in 2 volunteers and total serum cortisol in 3 volunteers.

Table 2. Dexamethasone suppression test in female volunteers treated with oral contraceptive therapy
All women, taking OCPa
(n = 47)

OCP with EE < 30 mcg OCP with EE ≥ 30 mcg
P
(n = 13)
(n = 34)
value

Age, years, median (IQR)
BMI, kg/m2, median (IQR)
Dexamethasone concentration,b,c mcg/dL, median
(IQR)
Dexamethasone concentration,b,c ≥0.1 mcg/dL, number
(%)
Total serum cortisol,b,c mcg/dL, median (IQR)
Total serum cortisol > 1.8,b,c mcg/dL, number (%)
Free serum cortisol,b,d ng/dL, median (IQR)

27 (24, 30)
24.5 (22.4, 28.3)
0.37 (0.24, 0.43)

26 (23, 27.5)
25.4 (22.5, 28.6)
0.37 (0.20, 0.45)

28 (25, 34)
24.5 (22.2, 28.2)
0.36 (0.26, 0.43)

0.06
0.53
0.92

45 (95.7)

11 (84.6)

34 (100)

0.07

1.3 (1.1 ,1.9)
12 (25.5)
33 (24 ,47)

1.3 (0.9, 2.9)
3 (23.1)
35 (22 ,53)

1.3 (1.2, 1.9)
9 (26.5)
32 (25 ,45.5)

0.29
0.81
0.12

Free serum cortisol within reference range,b,d number (%)

44 (93.6)

11 (84.6)

33 (97.1)

0.18

Abbreviations: BMI, body mass index; EE, ethinyl estradiol; IQR, interquartile range; OCP, oral contraceptive pill.
a
OCP use group included all women who received estrogen-containing oral contraceptive. Women who were on progestin only contraceptive therapy (n = 2) were
considered in the non-OCP group.
b
Dexamethasone concentration, total serum cortisol, and free serum cortisol were collected after 1 mg oral dexamethasone suppression.
c
Data unavailable for dexamethasone concentration in 2 volunteers and total serum cortisol in 3 volunteers.
d
Reference range free cortisol ≤ 79 ng/dL for women on OCP.
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Overall, median post-DST total cortisol was 0.79 mcg/dL
(IQR 0.60, 1.30), higher in women taking OCP compared with
those who were not (median of 1.30 vs 0.72 mcg/dL in women
not on OCP and 0.64 in men, P = 0.002), Table 1. Among 18
(11%) participants with post-DST total cortisol >1.8 mcg/dL,
12 (67%) were women taking OCP. About one-quarter of
women taking OCP had abnormal post-DST cortisol when
compared with other participants (26.5% vs 4.3%, P < 0.001).
The dose of ethinyl estradiol was not associated with any differences in post-DST total or free cortisol, Table 2. After excluding
women treated with OCP, no associations between post-DST
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P = 0.70), Table 1. Overall, post-DST free cortisol was
strongly correlated with post-DST total cortisol, R2 = 0.89
with a linear correlation (Fig. 1A).
Reference range for post-DST free cortisol were determined by first excluding any participants with inadequate dexamethasone concentrations (<0.1 ng/dL) (n = 4),
and excluding outliers (n = 4); supplemental Fig. 2 (18).
With this approach, the post-DST free cortisol maximum
level was ≤ 48 ng/dL for men and women not on OCP
and ≤ 79 ng/dL for women on OCP. The remaining participants’ total cortisol and free cortisol concentrations had
a strong correlation with binomial fit (R2 = 0.91); supplemental Fig. 3 (18). This relationship was very strong for
men and for women not taking OCP (R2 = 0.96), but was
more dispersed for women taking OCP (R2 = 0.63) (data
not shown).

Patients
One hundred and ninety-six patients participated in the
study at a median age of 57 years (IQR 40, 66), consisting
of 67% women (of whom 13 [10%] were taking OCP),
Table 3. Indications for DST varied, including evaluation of
adrenal mass (152, 77.6%), evaluation of pituitary mass (8,
4.1%), and evaluation for Cushing syndrome (24, 12.2%);
among all patients, there were concerns for overt Cushing
syndrome in 19 (9.7%).
Adequate dexamethasone concentrations were demonstrated in the majority of patients, suggestive of an optimal
compliance and absorption/metabolism of dexamethasone, with similar rates to healthy volunteers (96.3% and
97.6%, respectively; P = 0.56). Patients with inadequate
dexamethasone concentrations had higher post-DST total
and free cortisol when compared with patients with adequate dexamethasone concentrations (supplemental Table

2) (18), without any patient characteristics differentiating
the groups.
Among patients in whom DST was ordered as part of
clinical care, 100 (51%) had hypercortisolism excluded
(defined as post-DST total cortisol <1.8 mcg/dL), 65 (33%)
had a post-DST total cortisol between 1.8 and 5 mcg/dL,
and 31 (16%) had post-DST total cortisol >5 mcg/dL.
Overall, post-DST total cortisol correlated with post-DST
free cortisol (Fig. 1B); 100% of post-DST free cortisol was
above upper limit of normal in patients with post-DST cortisol >5 mcg/dL, but in only 70.7% of those with post-DST
cortisol between 1.8 and 5 mcg/dL (Table 3).
After exclusion of 7 (3.6%) patients with inadequate
dexamethasone concentrations, a total of 24 (12.7%) patients demonstrated a discordance between the post-DST
total and free cortisol (Fig. 2). Nineteen patients (21%) had
abnormal post-DST total cortisol but had a post-DST free
cortisol in the reference range (false-positive results), Table
4. The only patient characteristic associated with this discordance was OCP use (21.1% in the false-positive group
vs 4.7%, P = 0.02); no patients with discordant results had
clinical features consistent with overt Cushing syndrome.
None of the patients with false-positive results had a postDST total cortisol >5 mcg/dL, Table 4. When compared
with the post-DST free cortisol concentrations, post-DST
total cortisol had diagnostic accuracy of 87.3% (95% CI,
81.7-91.7), Fig. 2.

Discussion
We aimed to develop reference ranges for post-DST free cortisol concentrations in subjects without adrenal disorders
and to determine the utility of post-DST free cortisol assessment in patients evaluated for cortisol excess. We found
that the addition of post-DST free cortisol was particularly
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Figure 1. Post-dexamethasone suppression test: free cortisol vs total cortisol concentrations in (A) volunteers and (B) in patients undergoing evaluation for hypercortisolism.
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Table 3. Characteristics of participants and the results of dexamethasone suppression test
Patients

(n = 168)

(n = 196)

Patients based on post-DST total cortisol concentrations
Post-DST

Post-DST

Post-DST

Post-DST

TC ≤ 1.8 mcg/dL

TC > 1.8 mcg/dL

TC 1.8-5 mcg/dL

TC > 5 mcg/dL

(n = 100)

(n = 96)

(n = 65)

(n = 31)

29.5 (26, 40)

57 (40, 66)

56 (38.5, 63.8)

58 (42, 68)

61 (52, 71)

44 (30, 60)

113 (67.3)

132 (67.3)

60 (60)

72 (74.2)

46 (69.7

26 (83.9)

25.4

31.0

31.5

30.9

30.4

30.9

(22.8, 29.2)

(27.1, 37.5)

(28.1, 37.4)

(25.5, 37.5)

(25.1, 37.9)

(26.5, 36.6)

47 (28.0)

13 (6.6)

5 (5.1)

8 (8.2)

4 (6.1)

4 (12.9)

30

30

30

25

32.5

20

(20, 35)

(20, 35)

(20, 32.5)

(20, 35)

(22.5, 35)

(20, 31.3)

median (IQR)
Women, n (%)
BMI, kg/m2,
median (IQR)
Oral estradiol use,a n (%)
Estradiol dose, mcg, median (IQR)
Dexamethasone concentration,b,c mcg/dL,

0.34

0.46

0.45

0.47

0.49

0.45

median (IQR)

(0.25, 0.44)

(0.32, 0.62)

(0.33, 0.58)

(0.32, 0.73)

(0.33, 0.84)

(0.21, 0.63)

Dexamethasone concentrationb,c ≥0.1 mcg/

162 (97.6)

182 (96.3)

100 (100)

83 (92.2)

62 (95.4)

23 (87.1)

dL, n (%)
Total serum cortisol,b,c mcg/dL, median
(IQR)
Free serum cortisol,b,d ng/dL, median (IQR)

0.8

1.8

1.2

3.4

2.7

11

(0.6, 1.3)

(1.2, 3.4)

(0.8, 1.5)

(2.3, 8.5)

(2.1, 3.5)

(8.7, 15)

24

44

20

92

60

369

(19.3, 32.0)

(20, 90)

(20, 38.4)

(55.2, 240.5)

(46, 92.6)

(259, 449)

4 (4.2)

82 (41.8)

5 (5)

77 (79.4)

46 (70.7)

31 (100)

Discordant free to total cortisol, n (%)

11 (6.7)

24 (12.2)

5 (5)

19 (19.6)

19 (29.2)

0 (0)

Clinical evidence of overt Cushing syn-

0 (0)

19 (9.7)

0 (0)

19 (19.6)

5 (7.7)

14 (45.2)

Free serum cortisol above reference
range,b,d n (%)

drome, n (%)
Abbreviations: BMI, body mass index; DST, dexamethasone suppression test; IQR, interquartile range; OCP, oral contraceptive pill; TC, total cortisol.
OCP use group included all women who received estrogen-containing oral contraceptive. Women who were on progestin only contraceptive therapy (n = 2) were
considered in the non-OCP group.
b
Dexamethasone concentration, total serum cortisol, and free serum cortisol were collected after 1 mg oral dexamethasone suppression.
c
Data unavailable for dexamethasone concentration in 2 volunteers and total serum cortisol in 3 volunteers.
d
Reference range free cortisol for men and women not on OCP was ≤ 48 ng/dL and ≤ 79 ng/dL for women on OCP.
a

useful when total cortisol was between 1.8 and 5 mcg/dL,
which allowed reclassification of 30% of patients with abnormal post-DST total cortisol as false positive. Post-DST
free cortisol also allowed for enhanced interpretation of
dexamethasone suppression testing in women taking OCP.
We found that when compared with free cortisol, the diagnostic accuracy of post-DST total cortisol was 87%.
We observed adequate dexamethasone concentrations in
97.6% of volunteers and 96.3% of patients, suggesting that
compliance was high and abnormal metabolism/absorption
of dexamethasone was infrequent. Dexamethasone assays
vary, with cutoffs suggestive of optimal concentrations ranging between 0.10 and 0.18 mcg/dL in other studies (8-10,
19, 20). Interestingly, other studies attributed 6% to 20% of
false-positive post-DST total cortisol results to inadequate
dexamethasone concentrations (Table 5), a much higher
rate than what we observed. These differences may be due
to retrospective nature of most other studies, differences
in provided patient instruction on administration of dexamethasone, lack of optimal referent standard/control, and

a smaller sample size with possible selection bias. Our findings suggest that routine measurement of dexamethasone
concentrations may not be needed and should be reserved
only when noncompliance or abnormal dexamethasone absorption or metabolism is suspected.
We have observed that post-DST total cortisol was
normal in 75% of women treated with OCPs. Although the
Endocrine Society guidelines recommend cessation of oral
estrogens for 6 weeks before DST (2), our findings indicate
that it is reasonable to consider completing DST in patients
taking OCP, and considering an alternative option only in
those with abnormal results. This approach would likely
be less burdensome for patients and may reduce the risk of
unwanted pregnancy or other symptoms for which OCPs
were prescribed.
We found that both post-DST total and free cortisol concentrations are higher in women taking OCPs, though this
difference is smaller for the free cortisol. This finding can
be explained by the observation that approximately 80%
and 90% of total cortisol transported by cortisol binding
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Table 4. Characteristics of patients with adequate dexamethasone concentrations and false positive post-DST total cortisol

Age, y,
median (IQR)
Women,
number (%)
BMI, kg/m2,
median (IQR)
Oral estradiol use,d
number (%)
Dexamethasone concentration,e mcg/dL,
median (IQR)
Total serum cortisol,e mcg/dL,
median (IQR)
Total serum cortisol,c,d
1.8-5 mcg/dL
number (%)
> 5 mcg/dL
Free serum cortisol,e ng/dL,
median (IQR)
Clinical evidence of overt Cushing syndrome,
number (%)

All patientsa
(n = 189)

False positive
resultsb
(n = 19)

57 (40, 66)

57 (35, 64)

126 (66.7)
31.0 (27.3, 37.5)
12 (6.3)

13 (68.4)
31.4 (25.5, 37.7)
4 (21.1)

Concordant resultsc
(n = 165)

P value

56 (39.5, 66.5)

0.99

111 (67.3)

0.92

31.0 (27.4, 37.5)

0.66

8 (4.9)

0.02

0.47 (0.34, 0.63)

0.49 (0.41, 0.59)

0.46 (0.33, 0.63)

0.32

1.7 (1.2, 3.4)

2.2 (2.0, 2.4)

1.6 (1.1, 3.5)

0.27

62 (32.8)
27 (14.3)
43 (20, 79.5)

19 (100)
0 (0)
42 (39, 45.8)

43 (26.1)
27 (16.4)
43 (20, 92.3)

<0.0001
<0.0001
0.09

19 (11.2)

0.0001

19 (10.0)

0 (0)

Abbreviations: BMI, body mass index; DST, dexamethasone suppression test; EE, ethinyl estradiol; IQR, interquartile range; OCP, oral contraceptive pill.
a
Included only patients with dexamethasone concentration ≥ 0.1 mcg/dL (n = 7 excluded).
b
False-positive results were defined as those with abnormal post-DST total cortisol suggesting hypercortisolism, but normal post-DST free cortisol.
c
Concordant results were defined as those where presence or absence of hypercortisolism with DST was concordant whether interpreted with total cortisol or with
free cortisol.
d
OCP use group included all women who received estrogen-containing oral contraceptive. Women who were on progestin only contraceptive therapy (n = 2) were
considered in the non-OCP group.
e
Dexamethasone concentration, total serum cortisol, and free serum cortisol were collected after 1 mg oral dexamethasone suppression.
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Figure 2. Diagnostic accuracy of post-DST free cortisol concentrations. True-positive result was defined as a case with increased post-DST free cortisol and total cortisol. True-negative result was defined as absence of normal post-DST free cortisol and total cortisol. False-positive result was defined as abnormal post-DST total cortisol, but normal post-DST free cortisol. False-negative result was defined as normal post-DST total cortisol, but
abnormal post-DST free cortisol. Abbreviations: DST: dexamethasone suppression test; OCP: oral contraceptive pill.

Retrospective

Prospective

Vogg et al (2021) (20)

Current study (Genere et al)

Abbreviations: CS, Cushing syndrome; DST, dexamethasone suppression test; OCP, oral contraceptive pill.

0.10

0.10

Retrospective
Roper et al (2021) (10)

400 patients, 100 overt CS, 200 excluded CS, 100 adrenal incidentalomas and possible glucocorticoid autonomy (4.5% OCP use)
168 healthy volunteers (28% OCP use)
196 patients, consecutively enrolled (7% OCP use)

0.14, 0.18

Retrospective
Prospective
Ceccato et al (2020) (9)

63 patients with 70 samples

0.18

Retrospective
DeGraaf et al (2019) (19)

125 patients
75 patients, consecutively enrolled

0.16

0.13
Prospective
Ueland et al (2017) (8)

101 healthy volunteers (2% OCP use)
201 patients, consecutively enrolled (7% OCP use)
1901 samples consecutively examined, unknown clinical
scenario

Dexamethasone
cutoff used, mcg/dL
Study type
Clinical study

Participants

20% false-positive rate attributed to inadequate dexamethasone concentration
10% absolute reduction in “positive” DSTs when lower limit
of dexamethasone concentration was raised from 2.5th
percentile to 5th percentile
6% had inadequate dexamethasone concentration
Up to 40% of patients with post-DST cortisol > 5 mcg/dL
had inadequate dexamethasone concentrations
14% false-positive rate attributed to inadequate dexamethasone concentration
7% had inadequate dexamethasone concentration < 2.5th,
and only 4% had undetectable levels (suggesting noncompliance)
3% false-positive rate attributed to inadequate dexamethasone concentration

Table 5. Summary of studies assessing adequate dexamethasone concentration for dexamethasone suppression test

globulin, whereas a minority is free cortisol (6%) (21, 22).
The impact of oral estrogen on total cortisol concentrations
is mediated through stimulation of the cortisol binding
globulin; however, free cortisol is still affected proportionally, and to a smaller degree. These minimal increases
in circulating free cortisol are likely not clinically significant given the absence of symptomatic hypercortisolism in
women taking OCP.
When the post-DST free cortisol cutoffs derived from
the volunteers without adrenal disorders were used in
the interpretation of DST results in the clinical setting,
the sensitivity of post-DST total cortisol was found to
be 92%, specificity was 83%, positive predictive value
was 79%, and negative predictive value was 95%,
with an overall diagnostic accuracy of 87%. Notably,
all false-positive results (abnormal post-DST total cortisol, normal post-DST free cortisol) occurred in patients with post-DST total cortisol between 1.8 and 5
mcg/dL, and results were concordant when cortisol was
>5 mcg/dL. Therefore, free cortisol testing is likely unnecessary with post-DST total cortisol >5 mcg/dL. After
excluding patients with inadequate dexamethasone concentrations, the only factor that we found to be associated with false-positive results was OCP use. We have
not found any association between age, sex, or BMI and
false-positive results. No other studies reported on the
combined interpretation of the serum post-DST free and
total cortisol concentrations.
The strengths of our study included a cross-sectional
design with a prospective consecutive enrollment, standardized instructions and conduct of DST, a relatively large
sample size, and inclusion of women treated with OCP
(something that has not been previously addressed). The
limitations of this study include a single institution design
at a referral center that led to inclusion of a higher proportion of patients with hypercortisolism (than what would
be observed in primary care setting). Volunteers were not
assessed with a full battery of testing for hypercortisolism,
and it is possible that a small minority of volunteers may
have had an adrenal disorder that was missed by the interview or clinical examination. Our volunteer cohort was
also younger than patient cohort, and future investigations
may be helpful to understand the applicability of the reference range to an older population. Future studies should
include a prospective multicenter design, inclusion of a
higher number of volunteers, and cross-validation of assays used in different laboratories. In addition, although
we established the free cortisol cutoffs based on a cohort of
volunteers without adrenal disorders, the accuracy of these
cutoffs, as well as clinical significance of any discordance
between free cortisol and total cortisol, should be further
investigated.

Interpretation
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Clinical Implications
Based on the results of this study, we suggest a sequential approach to DST in clinical practice (Fig. 3). After
providing optimal instructions, we propose that DST is
performed in patients suspected to have cortisol excess
regardless of special circumstances, such as OCP use. If
post-DST total cortisol is >1.8 mcg/dL, we suggest measurements of dexamethasone concentrations on the stored
serum. In patients with abnormal DST and adequate dexamethasone concentrations, we suggest proceeding with the
free cortisol measurements only in the group of patients

with post-DST total cortisol between 1.8 and 5 mcg/dL (because no false-positive results were found when post-DST
total cortisol was >5 mcg/dL); Fig. 3. In conclusion, we
found that post-DST free cortisol evaluation is particularly
useful in patients with adequate dexamethasone concentrations and mildly abnormal post-DST total cortisol between
1.8 and 5 mcg/dL.

Acknowledgments
The authors are grateful to our patients and volunteers for their
participation and acknowledge the Mayo Clinic Laboratories

Downloaded from https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgab724/6396953 by Henry Ford Hospital / Sladen Library user on 17 December 2021

Figure 3. Suggested algorithm for the 1 mg overnight dexamethasone suppression test.
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